<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0510211105
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRUMENBA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MENINGOCOCCAL GROUP A (NEISSERIA MENINGITIDIS) POLYSACCHARIDE VACCINE,MENINGOCOCCAL GROUP B (NEISSERIA MENINGITIDIS) (STRAIN NZ98/254)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60,60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        313.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AH09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trumenba is a vaccine to prevent invasive meningococcal disease, caused by <em>Neisseria&nbsp;meningitidis </em>serogroup B, for use in people 10 years and older. This is a type of bacteria that can cause serious and sometimes life threatening infections such as meningitis (inflammation of the covering of the brain and spinal cord) and sepsis (blood poisoning).</p><p>&nbsp;</p><p>The vaccine contains 2 important components from the surface of the bacteria.</p><p>&nbsp;</p><p>The vaccine works by helping the body to make antibodies (the body&rsquo;s natural defences) which protect you or your child against this disease.</p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Trumenba should not be given</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or your child are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before vaccination with Trumenba. Tell your doctor, pharmacist or nurse if you or your child:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a severe infection with a high fever. If this is the case, then vaccination will be postponed. The presence of a minor infection, such as a cold, should not require postponement of the vaccination, but talk to your doctor first.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a bleeding problem or bruise easily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a weakened immune system which may prevent you or your child from getting the full benefit from Trumenba.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had any problems after any dose of Trumenba such as an allergic reaction or problems with breathing.</p><p>&nbsp;</p><p>Fainting, feeling faint, or other stress-related reactions can occur as a response to any needle injection. Tell your doctor, pharmacist or nurse if you have experienced this kind of reaction previously.</p><p>&nbsp;</p><p><strong>Other medicines and Trumenba</strong></p><p>Tell your doctor, pharmacist or nurse if you or your child are using, have recently used or might use any other medicines or have recently received any other vaccine.</p><p>&nbsp;</p><p>Trumenba can be given at the same time as any of the following vaccine components: tetanus, diphtheria, whooping cough (pertussis), poliovirus, papillomavirus, and meningococcal serogroups A, C, W, Y.</p><p>&nbsp;</p><p>Administration of Trumenba with vaccines other than those mentioned above, has not been studied.</p><p>&nbsp;</p><p>If you receive more than 1 vaccination at the same time it is important that different injection sites are used.</p><p>&nbsp;</p><p>If you take medicines that affect your immune system (such as radiation therapy, corticosteroids, or some types of cancer chemotherapies), you may not get the full benefit of Trumenba.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before Trumenba is given. Your doctor may still recommend that you receive Trumenba if you are at risk of meningococcal disease.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Trumenba has no or little influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>However, some of the side effects mentioned under section 4 &lsquo;Possible side effects&rsquo; may temporarily affect you. If this occurs, wait until the effects wear off before driving or using machines.</p><p>&nbsp;</p><p><strong>Trumenba contains sodium</strong></p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trumenba will be given to you or your child by a doctor, pharmacist or nurse. It will be injected into the upper arm muscle.</p><p>&nbsp;</p><p>It is important to follow the instructions from the doctor, pharmacist or nurse so that you or your child completes the course of injections.</p><p>&nbsp;</p><p><strong>Individuals 10 years </strong><strong>and older</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your child will receive 2 injections of the vaccine, the second injection is given 6 months after the first injection;</p><p>or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your child will receive 2 injections of the vaccine given at least 1 month apart and a third injection at least 4 months after the second injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your child may be given a booster.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines, this vaccine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>When Trumenba is given to your or your child, the following side effects may occur:</p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, swelling and pain at injection site</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever &ge;38 &deg;C</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center : 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website :https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp; <em>Please</em><em> contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&nbsp;&deg;C‑8&nbsp;&deg;C).</p><p>&nbsp;</p><p>Syringes should be stored in the refrigerator horizontally to minimize the re-dispersion time.</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>One dose (0.5&nbsp;ml) contains:</p><p>&nbsp;</p><p>Active substances:</p><p>&nbsp;</p><p><em>Neisseria meningitidis</em> serogroup B fHbp subfamily A<sup>1,2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>60&nbsp;micrograms</p><p><em>Neisseria meningitidis</em> serogroup B fHbp subfamily B<sup>1,2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>60&nbsp;micrograms</p><p>&nbsp;</p><p><sup>1</sup> Recombinant lipidated fHbp (factor H binding protein)</p><p><sup>2</sup> Produced in <em>Escherichia coli </em>cells by recombinant DNA technology</p><p><sup>3</sup> Adsorbed on aluminium phosphate (0.25&nbsp;milligram aluminium per dose)</p><p>&nbsp;</p><p>Other ingredients:</p><p>&nbsp;</p><p>Sodium chloride (see section 2 <strong>Trumenba contains sodium</strong>), histidine, water for injections, and polysorbate 80 (E433).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                		
	Trumenba is a white suspension for injection, provided in a pre-filled syringe. 
	
	Pack sizes of 1 pre-filled syringes with needles.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Pfizer Europe MA EEIG, Belgium</p><p>&nbsp;</p><p><strong>Manufactured by</strong></p><p>Pfizer Ireland Pharmaceuticals</p><p>Grange Castle Business Park, Dublin, Ireland</p><p>&nbsp;</p><p><strong>Packed &amp; Released by</strong></p><p>Pfizer Manufacturing Belgium NV</p><p>Rijksweg 12</p><p>2870 Puurs-Sint-Amands, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ترومينبا هو لقاح يُستعمل لمنع مرض المكورات السحائية الاجتياحي، الناتج عن النيسرية السحائية (نيسيريا مينينجيتيديس) من الزمرة المصلية B، للاستخدام للفئة العمرية ۱۰ أعوام وأكبر. هذا النوع من البكتيريا يمكن أن يتسبب في حالات عدوى خطيرة وأحيانًا مهددة للحياة مثل التهاب السحايا (التهاب الغشاء المغطي للمخ والحبل الشوكي) والإنتان (تسمم الدم).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي اللقاح على مكونين مهمين من سطح البكتيريا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يعمل هذا اللقاح عن طريق مساعدة الجسم على إنتاج أجسام مضادة (الدفاع الطبيعي للجسم) تحميك أنت أو طفلك من هذا المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال ترومينبا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أنت أو طفلك بحساسية تجاه المادة الفعالة أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ترومينبا </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تلقيحك بترومينبا. أخبر طبيبك أو الصيدلي أو الممرضة في حالة إصابتك أنت أو طفلك بما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة مع حمى مرتفعة. إذا كان الأمر كذلك، فحينئذ سيتم تأجيل التلقيح. ينبغي ألا يتطلب وجود عدوى بسيطة، مثل البرد، تأجيل التلقيح، ولكن تحدث مع طبيبك أولًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة متعلقة بالنزيف أو التعرض للتكدم بسهولة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الجهاز المناعي الذي قد يمنعك أنت أو طفلك من الحصول على الاستفادة الكاملة من ترومينبا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث أي مشكلات بعد تناول أي جرعة من ترومينبا مثل تفاعلات الحساسية أو مشكلات بالتنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث إغماء أو شعور بالإغماء أو تفاعلات أخرى مرتبطة بعامل الضغط كاستجابة للحقن بالإبرة. أخبر طبيبك أو الصيدلي أو الممرضة إذا تعرضت في السابق لهذا النوع من التفاعلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تستخدم أنت أو طفلك أو استخدمتما مؤخرًا أو قد تستخدمان أي أدوية أخرى أو تلقيتما مؤخرًا أي لقاحات أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء ترومينبا في نفس الوقت مع أي من مكونات اللقاح التالية: الكُزاز، والدفتيريا، والسعال الديكي (الشاهوق)، وفيروس شلل الأطفال، وفيروس الورم الحليمي، والمكورات السحائية ذات الزمرة المصلية A، C، W، Y.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تتم دراسة استعمال ترومينبا مع لقاحات أخرى بخلاف المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتلقى أكثر من لقاح في نفس الوقت، فمن المهم أن يتم استخدام مواضع حقن مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول أدوية تؤثر على جهازك المناعي (مثل العلاج الإشعاعي أو الستيرويدات القشرية أو بعض أنواع العلاجات الكيميائية للسرطان)، فقد لا تحصل على الاستفادة الكاملة من ترومينبا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو كنتِ تخططين للإنجاب، فاستشيري طبيبكِ قبل أن يتم إعطاؤكِ ترومينبا. قد يستمر طبيبكِ في التوصية بتلقي ترومينبا إذا كنتِ معرضةً لخطر الإصابة بمرض المكورات السحائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ترومينبا على القيادة واستخدام الآلات </strong></p><p dir="RTL">لا يوجد تأثير لترومينبا أو يوجد له تأثير طفيف على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ومع ذلك، قد تؤثر عليك بشكل مؤقت بعض الآثار الجانبية المذكورة تحت القسم ٤ &quot;الأعراض الجانبية&quot;. إذا حدث ذلك، فانتظر حتى تزول الآثار قبل القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات ترومينبا</strong></p><p dir="RTL"><strong>يحتوي ترومينبا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من ۱ مليمول من الصوديوم (۲۳ ملجم) في كل جرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم الطبيب أو الصيدلي أو الممرضة بإعطائك أنت أو طفلك ترومينبا. سيتم حقنه في عضلة الجزء العلوي من الذراع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم اتباع تعليمات الطبيب أو الصيدلي أو الممرضة حتى تستكمل أنت أو طفلك دورة العلاج بالحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأفراد في عمر </strong><strong>۱۰</strong><strong> أعوام وأكبر</strong></p><p dir="RTL">سوف تتلقى أنت أو طفلك حقنتين من اللقاح، وتُعطى الحقنة الثانية بعد ٦ أشهر من الحقنة الأولى؛</p><p dir="RTL">أو</p><p dir="RTL">سوف تتلقى أنت أو طفلك حقنتين من اللقاح، يجب أن يفصل بينهما شهر واحد على الأقل، وحقنة ثالثة بعد ٤ أشهر على الأقل من الحقنة الثانية.</p><p dir="RTL">قد تتلقى أنت أو طفلك جرعة مُعززة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع اللقاحات، يمكن أن يسبب هذا اللقاح أثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم إعطاؤك أنت أو طفلك ترومينبا، قد تحدث الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من بين كل ۱۰ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار موضع الحقن وتورمه والشعور بألم فيه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى بدرجة حرارة أكثر من أو تساوي ۳۸ درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً إلى المركز الوطني للتيقظ والسلامة الدوائية. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><ul><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في البراد (الثلاجة) (درجة حرارة تتراوح من درجتين مئويتين إلى 8 درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن تُخزن المحاقن في البراد (الثلاجة) بشكل أفقي لتقليل وقت إعادة التشتت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمّد الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جرعة واحدة (۰,٥ مل) تحتوي على:</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الفعالة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">النيسرية السحائية (نيسيريا مينينجيتيديس) من الزمرة المصلية B مكون من البروتين الرابط للعامل (fHbp) H، المجموعة الفرعية A<sup>١،٢،٣</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٦۰ ميكروجرامًا</p><p dir="RTL">النيسرية السحائية (نيسيريا مينينجيتيديس) من الزمرة المصلية B مكون من البروتين الرابط للعامل H، المجموعة الفرعية B<sup>١،٢،٣</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٦۰ ميكروجرامًا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><sup>١</sup> البروتين الدهني المأشوب الرابط للعامل H (البروتين الرابط للعامل H)</p><p dir="RTL"><sup>٢</sup> تم إنتاجه في خلايا بكتيريا الإشريكية القولونية (إيشريشيا كولاي) باستخدام تكنولوجيا الحمض النووي المأشوب</p><p dir="RTL"><sup>٣</sup> مُمتز على فوسفات الألومينيوم (۰,۲٥ مليجرام من الألومينيوم في كل جرعة)</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى:</p><p dir="RTL">&nbsp;</p><p dir="RTL">كلوريد الصوديوم (انظر القسم ۲ <strong>يحتوي ترومينبا على الصوديوم</strong>)، وهيستيدين، وماء للحقن، وبوليسوربات ٨٠ (E433).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يكون ترومينبا في صورة معلق أبيض اللون مخصص للحقن، معبأ في محقنة مسبقة التعبئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوة هي محقنة مسبقة التعبئة واحدة بإبر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق:</strong></p><p dir="RTL">Pfizer Europe MA EEIG, Belgium</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">Pfizer Ireland Pharmaceuticals</p><p dir="RTL">Grange Castle Business Park, Dublin, Ireland</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شركة التغليف والفسح النهائي:</strong></p><p dir="RTL">Pfizer Manufacturing Belgium NV</p><p dir="RTL">Rijksweg 12 Rijksweg 12</p><p>2870 Puurs-Sint-Amands, Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trumenba suspension for injection in pre-filled syringe

Meningococcal group B vaccine (recombinant, adsorbed)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 dose (0.5 ml) contains:

Neisseria meningitidis serogroup B fHbp subfamily A1,2,3		60 micrograms
Neisseria meningitidis serogroup B fHbp subfamily B1,2,3		60 micrograms
1 Recombinant lipidated fHbp (factor H binding protein)
2 Produced in Escherichia coli cells by recombinant DNA technology
3 Adsorbed on aluminium phosphate (0.25 milligram aluminium per dose) 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection.
White liquid suspension.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trumenba is indicated for active immunisation of individuals 10&nbsp;years and older to prevent invasive meningococcal disease caused by <em>Neisseria&nbsp;meningitidis </em>serogroup&nbsp;B.</p><p>&nbsp;</p><p>See section&nbsp;5.1 for information on the immune response against specific serogroup B strains.</p><p>&nbsp;</p><p>The use of this vaccine should be in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Primary series</em></p><p>2 doses: (0.5 ml each) administered at a 6 month interval (see section 5.1).</p><p>&nbsp;</p><p>3 doses: 2 doses (0.5 ml each) administered at least 1 month apart, followed by a third dose at least 4&nbsp;months after the second dose (see section 5.1).</p><p>&nbsp;</p><p><em>Booster dose</em></p><p>A booster dose should be considered following either dosing regimen for individuals at continued risk of invasive meningococcal disease (see section 5.1).</p><p>&nbsp;</p><p><em>Other paediatric populations </em></p><p>Safety and efficacy of Trumenba in children younger than 10&nbsp;years of age have not been established. Currently available data in infants are described in section 4.8 and for children 1&nbsp;to&nbsp;9&nbsp;years of age are described in sections 4.8 and 5.1; however, no recommendation on a posology can be made as data are limited.</p><p>&nbsp;</p><p>Trumenba should not be used in infants aged 2 to 6 months because of safety concerns (see section 4.8).</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For intramuscular injection only. The preferred site for injection is the deltoid muscle of the upper arm.</p><p>&nbsp;</p><p>For instructions on the handling of the vaccine before administration, see section 6.6.</p><p>&nbsp;</p><p>There are no data available on the interchangeability of Trumenba with other meningococcal group B vaccines to complete the vaccination series.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p><u>Syncope</u></p><p>&nbsp;</p><p>As with other injectable vaccines, syncope (fainting) can occur in association with administration of Trumenba. Procedures should be in place to avoid injury from fainting.</p><p>&nbsp;</p><p><u>Concurrent acute illness</u></p><p>&nbsp;</p><p>Vaccination should be postponed in individuals suffering from an acute severe febrile illness. However, the presence of a minor infection, such as cold, should not result in the deferral of vaccination.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Intramuscular injections</u></p><p>&nbsp;</p><p>Trumenba should not be administered intravenously, intradermally, or subcutaneously.</p><p>&nbsp;</p><p>Trumenba should not be given to individuals with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection, unless the potential benefit clearly outweighs the risk of administration.</p><p>&nbsp;</p><p><u>Altered immunocompetence </u></p><p><u>&nbsp;</u></p><p>Persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by <em>Neisseria meningitidis</em> serogroup B, even if they develop antibodies following vaccination with Trumenba.</p><p>&nbsp;</p><p><u>Protection against meningococcal disease</u></p><p>&nbsp;</p><p>As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients.</p><p>&nbsp;</p><p><u>Limitations of clinical trials</u></p><p><u>&nbsp;</u></p><p>There are no data on the use of Trumenba in immunocompromised individuals. Immunocompromised individuals, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Trumenba.</p><p>&nbsp;</p><p>There are limited data on the use of Trumenba in individuals 40 to 65 years of age and there are no data on the use of Trumenba in individuals older than 65 years of age.</p><p>&nbsp;</p><p><u>Excipient</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per dose. Individuals on low sodium diets can be informed that this medicinal product is essentially sodium-free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trumenba can be given concomitantly with any of the following vaccines: Tetanus Toxoid, Reduced Diphtheria Toxoid, Acellular Pertussis, and Inactivated Poliovirus Vaccine (TdaP-IPV), Quadrivalent Human Papillomavirus vaccine (HPV4), Meningococcal Serogroups A, C, Y, W conjugate vaccine (MenACWY) and Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap).</p><p>&nbsp;</p><p>When given concomitantly with other vaccines Trumenba must be administered at a separate injection site.</p><p>&nbsp;</p><p>Trumenba should not be mixed with other vaccines in the same syringe.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no data from the use of Trumenba in pregnant women. The potential risk for pregnant women is unknown. Nevertheless, vaccination should not be withheld when there is a clear risk of exposure to meningococcal infection.</p><p>&nbsp;</p><p>Reproduction studies performed in female rabbits have revealed no evidence of impaired female fertility or harm to the foetus due to Trumenba.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether Trumenba is excreted in human milk. Trumenba should only be used during breast-feeding when the possible advantages outweigh the potential risks.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to fertility in females (see section 5.3).</p><p>&nbsp;</p><p>Trumenba has not been evaluated for impairment of fertility in males.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trumenba has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety profile presented is based on analysis of approximately 17,000 subjects (1 year of age and older) who have been vaccinated with at least 1 dose of Trumenba in completed clinical studies.</p><p>&nbsp;</p><p>In over 16,000 subjects &ge;&nbsp;10 years of age studied, the most common adverse reactions were headache, diarrhoea, nausea, muscle pain, joint pain, fatigue, chills, and injection site pain, swelling and redness.</p><p>&nbsp;</p><p>Adverse reactions following booster vaccination in 301 subjects 15 to 23 years of age were similar to adverse reactions during the primary Trumenba vaccination series approximately 4 years earlier.<sup> </sup></p><p><u>&nbsp;</u></p><p><u>List of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported in clinical studies of subjects 10 years of age and older are listed in decreasing order of frequency and seriousness.</p><p>&nbsp;</p><p>Very common (&ge;&nbsp;1/10)</p><p>Common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10)</p><p>Uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100)</p><p>Rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)</p><p>Very rare (&lt;&nbsp;1/10,000)</p><p>Not known (cannot be estimated from available data)</p><p>&nbsp;</p><p><em>Immune system disorder</em></p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions*</p><p><u>&nbsp;</u></p><p><em>Nervous system disorders</em></p><p>Very Common: Headache</p><p><u>&nbsp;</u></p><p><em>Gastrointestinal disorders</em></p><p>Very Common: Diarrhoea; nausea</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p><u>&nbsp;</u></p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Very Common: Muscle pain (myalgia); joint pain (arthralgia)</p><p><u>&nbsp;</u></p><p><em>General disorders and administration site conditions</em></p><p>Very Common: Chills; fatigue; redness (erythema), swelling (induration) and pain at injection site</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever &ge;&nbsp;38 &deg;C (pyrexia)</p><p><u>&nbsp;</u></p><p>*Reported in the postmarketing experience. Because this reaction was derived from spontaneous reports, the frequency could not be determined and is thus considered as not known.</p><p>&nbsp;</p><p><u>Paediatric </u><u>population</u><u> </u><u>&lt; 10 years of age</u></p><p>&nbsp;</p><p><em>Children/toddlers</em></p><p>In a study of 294 children 2 to 9 years of age, the following adverse reactions occurred at a frequency of very common (&ge;&nbsp;1/10): headache, diarrhoea, vomiting, muscle pain, joint pain, fever, fatigue, and injection site pain, swelling and redness. Fever (&ge;&nbsp;38&nbsp;&deg;C) was reported in 24.5% of subjects.</p><p>&nbsp;</p><p>In a study of 220 toddlers 1 to &lt;&nbsp;2 years of age, the following adverse reactions occurred at a frequency of very common (&ge;&nbsp;1/10): drowsiness, irritability (fussiness), loss of or decreased appetite, fever, and injection site pain, swelling and redness. Fever (&ge;&nbsp;38&nbsp;&deg;C) was reported in 37.3% of subjects.</p><p>&nbsp;</p><p>In clinical studies, fever (&ge; 38&nbsp;&deg;C) occurred more frequently as subject age decreased. Fever followed a predictable pattern after vaccination: onset occurred within 2 to 4&nbsp;days, lasted 1&nbsp;day, and was mild to moderate in severity. Fever rate and severity tended to decrease with subsequent Trumenba vaccinations.</p><p>&nbsp;</p><p><em>Booster vaccination in children</em></p><p>Adverse reactions following a booster vaccination in 147 subjects 3 to 5&nbsp;years of age were similar to adverse reactions during the primary Trumenba vaccination series approximately 2&nbsp;years earlier.</p><p>&nbsp;</p><p><em>Infants less than 1 year of age</em></p><p>In a study including 115 infants 2 months and 48 infants 6 months of age who received Trumenba or an investigational combination meningococcal vaccine containing Trumenba co-administered with vaccines licensed for this age group, the following adverse reactions occurred at a frequency of very common (&ge; 1/10): drowsiness, irritability (fussiness), loss of or decreased appetite, fever, and injection site pain, swelling and redness.</p><p>&nbsp;</p><p>Fever (&ge; 38&nbsp;&deg;C) was reported in 74% of subjects, with 69% of subjects (33 out of 48) 6 months of age reporting fever and 76% of subjects (87 out of 115) 2 months of age. Occurrence of fever &gt;&nbsp;38.9&nbsp;&deg;C‑40.0&nbsp;&deg;C was very common (12.0-25.0%) in both age groups, despite the use of paracetamol. The rate and severity of fever did not decrease with the second vaccination in the youngest infants.</p><p>The study was terminated as two infants 2 months of age developed fever (39.3&nbsp;&deg;C and 39&nbsp;&deg;C, respectively) after the first vaccination that, despite the use of antipyretics, led to medical attention and investigations including lumbar puncture. Cerebrospinal fluid (CSF) analysis showed pleocytosis without positive microbiological test results in 1 infant. Both cases were treated as presumed infections. Symptoms resolved for both infants. Postmarketing data revealed 3 additional cases in which infants 1 to 3 months of age experienced fever leading to medical attention and investigations including lumbar puncture 1 day after administration of Trumenba. CSF analysis showed no pleocytosis in 2 cases and in 1 case showed pleocytosis without a positive microbiological test result.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the National Pharmacovigilance and Drug Safety Centre (NPC).</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other </strong><strong>GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience of overdose is limited. In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: vaccines; ATC code: J07AH09</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Trumenba is a vaccine composed of 2 recombinant lipidated factor H binding protein (fHbp) variants. fHbp is found on the surface of meningococcal bacteria and helps bacteria to avoid host immune defenses.&nbsp;fHbp variants segregate into 2 immunologically distinct subfamilies, A and B, and over 96% of meningococcal serogroup B isolates in Europe express fHbp variants from either subfamily on the bacterial surface.</p><p>&nbsp;</p><p>Immunisation with Trumenba, which contains one fHbp variant each from subfamily A and B, is intended to stimulate the production of bactericidal antibodies that recognise fHbp expressed by meningococci. The Meningococcal Antigen Surface Expression (MEASURE) assay was developed to relate the level of fHbp surface expression to killing of meningococcal serogroup B strains in serum bactericidal assays with human complement (hSBAs). A survey of over 2,150 different invasive meningococcal serogroup B isolates collected from 2000-2014 in 7 European countries, the US and Canada demonstrated that over 91% of all meningococcal serogroup B isolates expressed sufficient levels of fHbp to be susceptible to bactericidal killing by vaccine-induced antibodies.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy </u></p><p><u>&nbsp;</u></p><p>The efficacy of Trumenba has not been evaluated through clinical trials. Vaccine efficacy has been inferred by demonstrating the induction of serum bactericidal antibody responses to 4 meningococcal serogroup B test strains (see the Immunogenicity section).<strong><em> </em></strong>The 4 test strains express fHbp variants representing the 2 subfamilies (A and B) and, when taken together, are representative of meningococcal serogroup B strains causing invasive disease.</p><p>&nbsp;</p><p><u>Immunogenicity </u></p><p>&nbsp;</p><p>Protection against invasive meningococcal disease is mediated by serum bactericidal antibodies to bacterial surface antigens. Bactericidal antibodies act in concert with human complement to kill meningococci. This process is measured <em>in vitro </em>with hSBA for meningococcal serogroup B. An hSBA titre of &ge; 1:4 is assumed to be protective against meningococcal disease. In the immunogenicity analysis for Trumenba, a more conservative hSBA titre threshold of &ge; 1:8 or 1:16 was applied, depending on the hSBA strain.</p><p>&nbsp;</p><p>Vaccine coverage was investigated using four primary representative meningococcal serogroup B test strains: two expressing subfamily A fHbp (variants A22 and A56) and two expressing subfamily B fHbp (variants B24 and B44). To support and further extend the breadth of vaccine coverage, an additional 10 meningococcal serogroup B test strains were used; these included six expressing subfamily A fHbp (variants A06, A07, A12, A15, A19 and A29) and four expressing subfamily B fHbp (variants B03, B09, B15 and B16).</p><p>&nbsp;</p><p><em>Immunogenicity in subjects 10&nbsp;years of age and older</em></p><p>&nbsp;</p><p>The immunogenicity of Trumenba described in this section includes results from Phase 2 and Phase 3 clinical studies:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following the 2-dose schedule (0 and 6 months) in subjects 10 to 25 years of age in the US and Europe (Study B1971057);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following the 3-dose schedule (0, 2, and 6 months) in subjects 10 to 25&nbsp;years of age globally (Studies B1971009 and B1971016); and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following the 2-dose (0 and 6 months) and 3-dose schedules (0, 1-2, and 6 months) in subjects 11 to 18&nbsp;years of age in Europe (Study B1971012).</p><p>&nbsp;</p><p>Study B1971057 is a Phase 3, randomised, active-controlled, observer-blinded, multicentre trial in which subjects 10 to 25 years of age received Trumenba at months 0 and 6 (coadministered with MenACWY-CRM for the first dose) or an investigational pentavalent meningococcal vaccine at months 0 and 6. A total of 1,057 subjects received Trumenba and 543 subjects received the investigational control. The hSBA titres for primary test strains are presented in Table 1. Table 2 presents the hSBA titres against the additional 10 test strains which support and extend the breadth of vaccine coverage demonstrated by the 4 representative primary strains.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="10"><p><strong>Table 1: hSBA titres among subjects 10 to 25 years of age receiving Trumenba on a 0- and 6‑month schedule for primary strains 1 month post-dose 2 (Study B1971057)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" rowspan="2"><p><strong>&ge;&nbsp;4-fold rise<sup>(1)</sup></strong></p></td><td colspan="2" rowspan="2"><p><strong>Titre &ge;&nbsp;1:8</strong><strong><sup>(2)</sup></strong></p></td><td rowspan="2"><p><strong>GMT</strong><strong><sup>(3)</sup></strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Composite<sup>(4)</sup></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Pre-vaccination 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Post-dose 2</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Strain</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>%</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>%</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td><p><strong>A22</strong></p></td><td><p>827</p></td><td style="vertical-align:top"><p>73.8</p><p>(70.6, 76.7)</p></td><td><p>852</p></td><td style="vertical-align:top"><p>91.0</p><p>(88.8, 92.8)</p></td><td style="vertical-align:top"><p>49.3</p><p>(46.2, 52.6)</p></td><td rowspan="4"><p>799</p></td><td rowspan="4"><p>1.8<br />(1.0, 2.9)</p></td><td rowspan="4"><p>814</p></td><td rowspan="4"><p>74.3</p><p>(71.2, 77.3)</p></td></tr><tr><td><p><strong>A56</strong></p></td><td><p>823</p></td><td style="vertical-align:top"><p>95.0</p><p>(93.3, 96.4)</p></td><td><p>854</p></td><td style="vertical-align:top"><p>99.4</p><p>(98.6, 99.8)</p></td><td><p>139.5</p><p>(130.6, 149.1)</p></td></tr><tr><td><p><strong>B24</strong></p></td><td><p>835</p></td><td style="vertical-align:top"><p>67.4</p><p>(64.1, 70.6)</p></td><td><p>842</p></td><td><p>79.3</p><p>(76.4, 82.0)</p></td><td style="vertical-align:top"><p>21.2</p><p>(19.6, 22.9)</p></td></tr><tr><td><p><strong>B44</strong></p></td><td><p>850</p></td><td style="vertical-align:top"><p>86.4</p><p>(83.9, 88.6)</p></td><td><p>853</p></td><td style="vertical-align:top"><p>94.5</p><p>(92.7, 95.9)</p></td><td style="vertical-align:top"><p>37.8</p><p>(35.1, 40.8)</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p>Abbreviations: GMT=geometric mean titre; hSBA=serum bactericidal assay using human complement.</p><p><sup>(1)</sup> A &ge; 4-fold rise is defined as (i) A hSBA titre &ge;&nbsp;1:16 for subjects with a baseline hSBA titre &lt;&nbsp;1:4. (ii) Four times the 1:8 or 16 threshold or four times the baseline hSBA titre, whichever is higher for subjects with a baseline hSBA titre &ge;&nbsp;1:4.</p><p><sup>(2)</sup> All strains used a 1:8 titre threshold except A22 which was 1:16.</p><p><sup>(3)</sup> N for GMT is the same as that presented in preceding titre &ge;&nbsp;1:8 or 16 column.</p><p><sup>(4)</sup> Proportion of subjects with a composite of hSBA titres &ge;&nbsp;1:8 or 16 for all four primary strains combined.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 2:&nbsp;&nbsp; hSBA titres among subjects 10 to 25 years of age receiving Trumenba on a 0- and 6‑month schedule for additional strains 1 month post-dose 2 (Study B1971057)</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>% titre &ge; 1:8<sup>(1)</sup></strong></p></td><td><p><strong>95% CI</strong></p></td></tr></thead><tbody><tr><td><p><strong>A06</strong></p></td><td><p>159</p></td><td style="vertical-align:top"><p>89.3</p></td><td><p>83.4, 93.6</p></td></tr><tr><td><p><strong>A07</strong></p></td><td><p>157</p></td><td style="vertical-align:top"><p>96.8</p></td><td><p>92.7, 99.0</p></td></tr><tr><td><p><strong>A12</strong></p></td><td><p>157</p></td><td style="vertical-align:top"><p>83.4</p></td><td><p>76.7, 88.9</p></td></tr><tr><td><p><strong>A15</strong></p></td><td><p>165</p></td><td style="vertical-align:top"><p>89.1</p></td><td><p>83.3, 93.4</p></td></tr><tr><td><p><strong>A19</strong></p></td><td><p>167</p></td><td style="vertical-align:top"><p>90.4</p></td><td><p>84.9, 94.4</p></td></tr><tr><td><p><strong>A29</strong></p></td><td><p>166</p></td><td style="vertical-align:top"><p>95.2</p></td><td><p>90.7, 97.9</p></td></tr><tr><td><p><strong>B03</strong></p></td><td><p>164</p></td><td style="vertical-align:top"><p>74.4</p></td><td><p>67.0, 80.9</p></td></tr><tr><td><p><strong>B09</strong></p></td><td><p>166</p></td><td style="vertical-align:top"><p>71.1</p></td><td><p>63.6, 77.8</p></td></tr><tr><td><p><strong>B15</strong></p></td><td><p>167</p></td><td style="vertical-align:top"><p>85.0</p></td><td><p>78.7, 90.1</p></td></tr><tr><td><p><strong>B16</strong></p></td><td><p>164</p></td><td style="vertical-align:top"><p>77.4</p></td><td><p>70.3, 83.6</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Abbreviations: hSBA=serum bactericidal assay using human complement.</p><p><sup>(1)</sup> All strains used a 1:8 titre threshold except A06, A12 and A19 which were 1:16.</p></td></tr></tbody></table><p>&nbsp;</p><p>Study B1971009 was a Phase 3, randomised, active-controlled, observer-blinded, multicentre trial in which subjects 10 to 18 years of age received 1 of 3 lots of Trumenba or the active control hepatitis A virus (HAV) vaccine/saline (control). A total of 2,693 subjects received at least 1 dose of Trumenba and 897 received at least 1 dose of HAV vaccine/saline. The study assessed the safety, tolerability, immunogenicity, and demonstration of manufacturability of 3 lots of Trumenba administered on a 0-, 2-, and 6-month schedule. The hSBA titres for primary test strains observed after the third dose in lot 1 and the control are presented in Table 3. Results from lots 2 and 3 are not presented, as only 2&nbsp;representative strains were evaluated. Similar results were observed for lots 2 and 3 as observed for lot 1.</p><p>&nbsp;</p><p>Study B1971016 was a Phase 3, randomised, placebo-controlled, observer-blinded, multicentre trial in which subjects 18 to 25 years of age were assigned to receive either Trumenba at months 0, 2, and 6 or saline at months 0, 2, and 6 in a 3:1 ratio.<em> </em>A total of 2,471 subjects received Trumenba and 822 received saline. The hSBA titres for primary test strains observed after the third dose are presented in Table 3.</p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:109%"><thead><tr><td colspan="21" style="vertical-align:top"><p><strong>Table&nbsp;3. </strong> <strong>hSBA titres among subjects 10 to 25 years of age 1 month post-dose 3 of Trumenba or control on a 0-, 2-, and 6-month schedule for primary strains </strong><strong>(Study&nbsp;B1971009 and Study&nbsp;B1971016) </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="8" style="vertical-align:top"><p><strong>Study B1971009</strong></p><p><strong>(10-18 years of age)</strong></p></td><td colspan="10" style="vertical-align:top"><p><strong>Study B1971016</strong></p><p><strong>(18-25 years of age)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Trumenba</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>HAV/saline</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Trumenba</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Saline</strong></p></td></tr><tr><td colspan="3"><p><strong>Strain</strong></p></td><td colspan="2"><p><strong>N</strong></p></td><td colspan="2"><p><strong>% or GMT</strong></p><p><strong>(95% CI)</strong></p></td><td colspan="2"><p>N</p></td><td colspan="2"><p><strong>% or GMT</strong></p><p><strong>(95% CI)</strong></p></td><td colspan="2"><p><strong>N</strong></p></td><td colspan="2"><p><strong>%</strong> <strong>or GMT</strong></p><p><strong>(95% CI)</strong></p></td><td colspan="4"><p><strong>N</strong></p></td><td colspan="2"><p><strong>% or GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="3"><p><strong>A22</strong></p></td><td><p><strong>&ge;&nbsp;4-fold rise<sup>(1)</sup></strong></p></td><td colspan="2"><p>1225</p></td><td colspan="2"><p>83.2</p><p>(81.0, 85.2)</p></td><td colspan="2"><p>730</p></td><td colspan="2"><p>9.6</p><p>(7.6, 12.0)</p></td><td colspan="2"><p>1695</p></td><td colspan="2"><p>80.5</p><p>(78.6, 82.4)</p></td><td colspan="4"><p>568</p></td><td colspan="2"><p>6.3</p><p>(4.5, 8.7)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA &ge; 1:16</strong></p></td><td colspan="2"><p>1266</p></td><td colspan="2"><p>97.8</p><p>(96.8, 98.5)</p></td><td colspan="2"><p>749</p></td><td colspan="2"><p>34.0</p><p>(30.7, 37.6)</p></td><td colspan="2"><p>1714</p></td><td colspan="2"><p>93.5</p><p>(92.2, 94.6)</p></td><td colspan="4"><p>577</p></td><td colspan="2"><p>36.6</p><p>(32.6, 40.6)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA GMT</strong></p></td><td colspan="2"><p>1266</p></td><td colspan="2"><p>86.8</p><p>(82.3, 91.5)</p></td><td colspan="2"><p>749</p></td><td colspan="2" style="vertical-align:top"><p>12.6</p><p>(12.0, 13.4)</p></td><td colspan="2"><p>1714</p></td><td colspan="2"><p>74.3</p><p>(70.2, 78.6)</p></td><td colspan="4"><p>577</p></td><td colspan="2"><p>13.2</p><p>(12.4, 14.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p><strong>A56</strong></p></td><td><p><strong>&ge;&nbsp;4-fold rise<sup>(1)</sup></strong></p></td><td colspan="2"><p>1128</p></td><td colspan="2"><p>90.2</p><p>(88.4, 91.9)</p></td><td colspan="2"><p>337</p></td><td colspan="2"><p>11.3</p><p>(8.1, 15.1)</p></td><td colspan="2"><p>1642</p></td><td colspan="2"><p>90.0</p><p>(88.4, 91.4)</p></td><td colspan="4"><p>533</p></td><td colspan="2"><p>10.3</p><p>(7.9, 13.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA &ge;&nbsp;1:8</strong></p></td><td colspan="2"><p>1229</p></td><td colspan="2"><p>99.5</p><p>(98.9, 99.8)</p></td><td colspan="2"><p>363</p></td><td colspan="2"><p>27.5</p><p>(23.0, 32.5)</p></td><td colspan="2"><p>1708</p></td><td colspan="2"><p>99.4</p><p>(98.9, 99.7)</p></td><td colspan="4"><p>552</p></td><td colspan="2"><p>34.2</p><p>(30.3, 38.4)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA GMT</strong></p></td><td colspan="2"><p>1229</p></td><td colspan="2"><p>222.5</p><p>(210.1, 235.6)</p></td><td colspan="2"><p>363</p></td><td colspan="2"><p>8.8</p><p>(7.6, 10.1)</p></td><td colspan="2"><p>1708</p></td><td colspan="2"><p>176.7</p><p>(167.8, 186.1)</p></td><td colspan="4"><p>552</p></td><td colspan="2"><p>9.1</p><p>(8.2, 10.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p><strong>B24</strong></p></td><td><p><strong>&ge;&nbsp;4-fold rise<sup>(1)</sup></strong></p></td><td colspan="2"><p>1235</p></td><td colspan="2"><p>79.8</p><p>(77.4, 82.0)</p></td><td colspan="2"><p>752</p></td><td colspan="2"><p>2.7</p><p>(1.6, 4.1)</p></td><td colspan="2"><p>1675</p></td><td colspan="2" style="vertical-align:top"><p>79.3</p><p>(77.3, 81.2)</p></td><td colspan="4"><p>562</p></td><td colspan="2" style="vertical-align:top"><p>5.5</p><p>(3.8, 7.7)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA &ge;&nbsp;1:8</strong></p></td><td colspan="2"><p>1250</p></td><td colspan="2"><p>87.1</p><p>(85.1, 88.9)</p></td><td colspan="2"><p>762</p></td><td colspan="2"><p>7.0</p><p>(5.3, 9.0)</p></td><td colspan="2"><p>1702</p></td><td colspan="2"><p>95.1</p><p>(93.9, 96.0)</p></td><td colspan="4"><p>573</p></td><td colspan="2"><p>30.2</p><p>(26.5, 34.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA GMT</strong></p></td><td colspan="2"><p>1250</p></td><td colspan="2"><p>24.1</p><p>(22.7, 25.5)</p></td><td colspan="2"><p>762</p></td><td colspan="2"><p>4.5</p><p>(4.4, 4.7)</p></td><td colspan="2"><p>1702</p></td><td colspan="2"><p>49.5</p><p>(46.8, 52.4)</p></td><td colspan="4"><p>573</p></td><td colspan="2"><p>7.2</p><p>(6.6, 7.8)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p><strong>B44</strong></p></td><td><p><strong>&ge;&nbsp;4-fold rise<sup>(1)</sup></strong></p></td><td colspan="2"><p>1203</p></td><td colspan="2"><p>85.9</p><p>(83.8, 87.8)</p></td><td colspan="2"><p>391</p></td><td colspan="2"><p>1.0</p><p>(0.3, 2.6)</p></td><td colspan="2"><p>1696</p></td><td colspan="2" style="vertical-align:top"><p>79.6</p><p>(77.6, 81.5)</p></td><td colspan="4"><p>573</p></td><td colspan="2" style="vertical-align:top"><p>1.6</p><p>(0.7, 3.0)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA &ge;&nbsp;1:8</strong></p></td><td colspan="2"><p>1210</p></td><td colspan="2"><p>89.3</p><p>(87.4, 90.9)</p></td><td colspan="2"><p>393</p></td><td colspan="2"><p>5.3</p><p>(3.3, 8.1)</p></td><td colspan="2"><p>1703</p></td><td colspan="2"><p>87.4</p><p>(85.8, 89.0)</p></td><td colspan="4"><p>577</p></td><td colspan="2"><p>11.4</p><p>(9.0, 14.3)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>hSBA GMT</strong></p></td><td colspan="2"><p>1210</p></td><td colspan="2"><p>50.9</p><p>(47.0, 55.2)</p></td><td colspan="2"><p>393</p></td><td colspan="2"><p>4.4</p><p>(4.2, 4.6)</p></td><td colspan="2"><p>1703</p></td><td colspan="2"><p>47.6</p><p>(44.2, 51.3)</p></td><td colspan="2"><p>577</p></td><td colspan="4"><p>4.8</p><p>(4.6, 5.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="21" style="vertical-align:top"><p><strong>Composite</strong><strong><sup>(2)</sup></strong></p></td></tr><tr><td colspan="3"><p>&nbsp;&nbsp;&nbsp; Pre-vaccination 1</p></td><td colspan="2"><p>1088</p></td><td colspan="2"><p>1.1</p><p>(0.6, 1.9)</p></td><td colspan="2"><p>354</p></td><td colspan="2"><p>2.0</p><p>(0.8, 4.0)</p></td><td colspan="2"><p>1612</p></td><td colspan="2" style="vertical-align:top"><p>7.3</p><p>(6.0, 8.6)</p></td><td colspan="2"><p>541</p></td><td colspan="4" style="vertical-align:top"><p>6.1</p><p>(4.2, 8.5)</p></td></tr><tr><td colspan="3"><p>&nbsp;&nbsp; Post-dose 3</p></td><td colspan="2"><p>1170</p></td><td colspan="2"><p>83.5</p><p>(81.3, 85.6)</p></td><td colspan="2"><p>353</p></td><td colspan="2"><p>2.8</p><p>(1.4, 5.1)</p></td><td colspan="2"><p>1664</p></td><td colspan="2" style="vertical-align:top"><p>84.9</p><p>(83.1, 86.6)</p></td><td colspan="2"><p>535</p></td><td colspan="4" style="vertical-align:top"><p>7.5</p><p>(5.4, 10.0)</p></td></tr><tr><td colspan="21" style="vertical-align:top"><p>Abbreviations: GMT=geometric mean titre; hSBA=serum bactericidal assay using human complement; HAV=hepatitis A virus vaccine.</p><p><sup>(1)</sup> A &ge; 4-fold rise is defined as (i) A hSBA titre &ge;&nbsp;1:16 for subjects with a baseline hSBA titre &lt;&nbsp;1:4. (ii) Four times the 1:8/16 threshold or four times the baseline hSBA titre, whichever is higher for subjects with a baseline hSBA titre &ge; 1:4.</p><p><sup>(2) </sup>Proportion of subjects with a composite of hSBA titres &ge; 1:8 or 16 for all four primary strains combined.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><em>&nbsp;</em></p><p>In Studies B1971009 and B1971016, the proportion of subjects achieving a hSBA titre &ge; 1:8 (variants A07, A15, A29, B03, B09, B15, B16) or 1:16 (variants A06, A12, A19) against the 10&nbsp;additional test strains after 3&nbsp;doses of Trumenba, administered on a 0-, 2-, and 6-month schedule, was determined. Across the two studies, the majority of subjects, ranging from 71.3% to 99.3% for the 6 subfamily A fHbp strains and 77.0% to 98.2% for the 4 subfamily B fHbp strains, achieved a hSBA titre &ge;&nbsp;1:8 or 16, consistent with the results observed with the 4 primary test strains.</p><p><em>&nbsp;</em></p><p>In Study B1971012, a Phase 2 study in subjects 11 to 18 years of age in Europe, hSBA titres following completion of two 3-dose schedules (0, 1, and 6 months and 0, 2, and 6 months) and a 2-dose schedule (0 and 6 months) were determined against the 4 primary test strains. At 1 month after the third dose, similar robust and broad immune responses were observed for both 3-dose schedules with 86.1% to 99.4% achieving hSBA titres &ge;&nbsp;1:8 or 16 and 74.6% to 94.2% achieving a 4-fold increase in hSBA titre. At 1 month after completion of the 2-dose schedule (0 and 6 months), 77.5% to 98.4% achieved hSBA titres &ge;&nbsp;1:8 or 16 and 65.5% to 90.4% achieved a 4-fold increase in hSBA titre.</p><p>&nbsp;</p><p>Study B1971033 was an open-label, follow-up study of subjects previously enrolled in a primary study, including Study B1971012. Subjects attended visits over 4 years for collection of blood samples and received a single booster dose of Trumenba approximately 4 years after receipt of a primary series of 2&nbsp;or 3 doses of Trumenba. hSBA titres 4 years after the primary series and 26&nbsp;months after the booster dose for subjects enrolled from primary Study B1971012 Group 1 (0, 1, and 6 months), Group&nbsp;2 (0, 2, and 6 months), and Group 3 (0 and 6 months) are presented in Table 4. A booster response was observed as measured by hSBA at 1 month following a dose of Trumenba approximately 4&nbsp;years after a primary series of 2 doses (Group 3) or 3&nbsp;doses (Groups 1 and 2).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:690px"><thead><tr><td colspan="16" style="vertical-align:top"><p><strong>Table 4:&nbsp;&nbsp; hSBA titres among subjects 11 to 18 years of age receiving Trumenba on a 0-, 1-, 6-month; 0-, 2-, and 6-month; and 0- and 6-month schedules and a booster 4 years after primary series completion (Study B1971033)</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>Strain</strong></p></td><td colspan="2" rowspan="3" style="vertical-align:bottom"><p><strong>Timepoint</strong></p></td><td colspan="13" style="vertical-align:top"><p><strong>Primary Study B1971012 Vaccine Groups (as Randomised)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>0, 1, and 6 months</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>0, 2, and 6 months</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>0 and 6 months</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>% &ge;&nbsp;1:8<sup>(1)</sup> </strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>% &ge;&nbsp;1:8<sup>(1)</sup></strong></p><p><strong>(95% CI)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>N</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>% &ge;&nbsp;1:8<sup>(1)</sup></strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="6"><p><strong>A22</strong></p></td><td rowspan="3" style="vertical-align:top"><p>Post-primary</p></td><td><p>month 1</p></td><td><p>59</p></td><td style="vertical-align:top"><p>89.8</p><p>(79.2, 96.2)</p></td><td><p>53.0</p><p>(40.4, 69.6)</p></td><td><p>57</p></td><td><p>91.2</p><p>(80.7, 97.1)</p></td><td colspan="3"><p>59.5</p><p>(45.5, 77.8)</p></td><td colspan="2"><p>61</p></td><td colspan="2"><p>98.4</p><p>(91.2, 100.0)</p></td><td><p>55.8</p><p>(46.2, 67.4)</p></td></tr><tr><td><p>month 12</p></td><td><p>99</p></td><td><p>41.4</p><p>(31.6, 51.8)</p></td><td><p>14.9</p><p>(12.6, 17.7)</p></td><td><p>111</p></td><td><p>45.0</p><p>(35.6, 54.8)</p></td><td colspan="3"><p>15.8</p><p>(13.4, 18.6)</p></td><td colspan="2"><p>113</p></td><td colspan="2"><p>36.3</p><p>(27.4, 45.9)</p></td><td><p>15.6</p><p>(13.0, 18.8)</p></td></tr><tr><td><p>month 48</p></td><td><p>59</p></td><td><p>49.2</p><p>(35.9, 62.5)</p></td><td><p>16.6</p><p>(13.0, 21.1)</p></td><td><p>57</p></td><td><p>56.1</p><p>(42.4, 69.3)</p></td><td colspan="3"><p>20.7</p><p>(15.6, 27.4)</p></td><td colspan="2"><p>61</p></td><td colspan="2"><p>55.7</p><p>(42.4, 68.5)</p></td><td><p>16.6</p><p>(13.4, 20.5)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Post-booster</p></td><td><p>month 1</p></td><td><p>59</p></td><td><p>100.0</p><p>(93.9, 100.0)</p></td><td><p>126.5</p><p>(102.7, 155.8)</p></td><td><p>58</p></td><td><p>100.0</p><p>(93.8, 100.0)</p></td><td colspan="3"><p>176.7</p><p>(137.8, 226.7)</p></td><td colspan="2"><p>60</p></td><td colspan="2"><p>96.7</p><p>(88.5, 99.6)</p></td><td><p>142.0</p><p>(102.9, 196.1)</p></td></tr><tr><td><p>month 12</p></td><td><p>58</p></td><td><p>74.1<br />(61.0, 84.7)</p></td><td><p>33.6</p><p>(24.5, 46.1)</p></td><td><p>54</p></td><td><p>77.8<br />(64.4, 88.0)</p></td><td colspan="3"><p>44.1<br />(31.2, 62.4)</p></td><td colspan="2"><p>60</p></td><td colspan="2"><p>80.0<br />(67.7, 89.2)</p></td><td><p>31.6<br />(23.5, 42.5)</p></td></tr><tr><td><p>month 26</p></td><td><p>0</p></td><td><p>NE<sup>(2)</sup></p></td><td><p>NE<sup>(2)</sup></p></td><td><p>34</p></td><td><p>73.5<br />(55.6, 87.1)</p></td><td colspan="3"><p>34.7<br />(23.0, 52.4)</p></td><td colspan="2"><p>42</p></td><td colspan="2"><p>61.9<br />(45.6, 76.4)</p></td><td><p>27.1<br />(18.6, 39.6)</p></td></tr><tr><td rowspan="6"><p><strong>A56</strong></p></td><td rowspan="3"><p>Post-primary</p></td><td><p>month 1</p></td><td><p>58</p></td><td><p>100.0</p><p>(93.8, 100.0)</p></td><td><p>158.7</p><p>(121.5, 207.3)</p></td><td><p>57</p></td><td><p>98.2</p><p>(90.6, 100.0)</p></td><td colspan="3"><p>191.2</p><p>(145.8, 250.8)</p></td><td colspan="2"><p>62</p></td><td colspan="2"><p>98.4</p><p>(91.3, 100.0)</p></td><td><p>143.1</p><p>(109.6, 187.0)</p></td></tr><tr><td><p>month 12</p></td><td><p>98</p></td><td><p>73.5</p><p>(63.6, 81.9)</p></td><td><p>25.7</p><p>(19.4, 34.0)</p></td><td><p>109</p></td><td><p>76.1</p><p>(67.0, 83.8)</p></td><td colspan="3"><p>27.3</p><p>(21.0, 35.4)</p></td><td colspan="2"><p>106</p></td><td colspan="2"><p>60.4</p><p>(50.4, 69.7)</p></td><td><p>18.5</p><p>(13.8, 24.7)</p></td></tr><tr><td><p>month 48</p></td><td><p>53</p></td><td><p>43.4</p><p>(29.8, 57.7)</p></td><td><p>10.7</p><p>(7.4, 15.3)</p></td><td><p>55</p></td><td colspan="2"><p>56.4</p><p>(42.3, 69.7)</p></td><td colspan="3"><p>15.0</p><p>(10.2, 22.2)</p></td><td colspan="2"><p>62</p></td><td><p>43.5</p><p>(31.0, 56.7)</p></td><td><p>10.8</p><p>(7.6, 15.3)</p></td></tr><tr><td rowspan="3"><p>Post-booster</p></td><td><p>month 1</p></td><td><p>57</p></td><td><p>100.0</p><p>(93.7, 100.0)</p></td><td><p>359.8</p><p>(278.7, 464.7)</p></td><td><p>56</p></td><td colspan="2"><p>100.0</p><p>(93.6, 100.0)</p></td><td colspan="3"><p>414.8</p><p>(298.8, 575.9)</p></td><td colspan="2"><p>62</p></td><td><p>98.4</p><p>(91.3, 100.0)</p></td><td><p>313.1</p><p>(221.3, 442.8)</p></td></tr><tr><td><p>month 12</p></td><td><p>55</p></td><td><p>90.9<br />(80.0, 97.0)</p></td><td><p>47.3<br />(34.3, 65.3)</p></td><td><p>55</p></td><td colspan="2"><p>89.1<br />(77.8, 95.9)</p></td><td colspan="3"><p>64.0<br />(42.6, 96.2)</p></td><td colspan="2"><p>59</p></td><td><p>81.4<br />(69.1, 90.3)</p></td><td><p>41.0<br />(26.7, 62.7)</p></td></tr><tr><td><p>month 26</p></td><td><p>0</p></td><td><p>NE<sup>(2)</sup></p></td><td><p>NE<sup>(2)</sup></p></td><td><p>29</p></td><td colspan="2"><p>82.8<br />(64.2, 94.2)</p></td><td colspan="3"><p>37.8<br />(21.3, 67.2)</p></td><td colspan="2"><p>40</p></td><td><p>57.5<br />(40.9, 73.0)</p></td><td><p>16.0<br />(9.9, 25.8)</p></td></tr><tr><td rowspan="6"><p><strong>B24</strong></p></td><td rowspan="3"><p>Post-primary</p></td><td><p>month 1</p></td><td><p>59</p></td><td><p>88.1</p><p>(77.1, 95.1)</p></td><td><p>25.6</p><p>(19.7, 33.3)</p></td><td><p>58</p></td><td colspan="2"><p>91.4</p><p>(81.0, 97.1)</p></td><td colspan="3"><p>30.5</p><p>(23.8, 39.1)</p></td><td colspan="2"><p>60</p></td><td><p>85.0</p><p>(73.4, 92.9)</p></td><td><p>29.2</p><p>(21.5, 39.6)</p></td></tr><tr><td><p>month 12</p></td><td><p>98</p></td><td><p>40.8</p><p>(31.0, 51.2)</p></td><td><p>9.7</p><p>(7.5, 12.4)</p></td><td><p>108</p></td><td colspan="2"><p>49.1</p><p>(39.3, 58.9)</p></td><td colspan="3"><p>11.5</p><p>(9.0, 14.6)</p></td><td colspan="2"><p>103</p></td><td><p>36.9</p><p>(27.6, 47.0)</p></td><td><p>8.4</p><p>(6.7, 10.6)</p></td></tr><tr><td><p>month 48</p></td><td><p>59</p></td><td><p>40.7</p><p>(28.1, 54.3)</p></td><td><p>10.7</p><p>(7.6, 15.1)</p></td><td><p>57</p></td><td colspan="2"><p>49.1</p><p>(35.6, 62.7)</p></td><td colspan="3"><p>11.4</p><p>(8.2, 15.9)</p></td><td colspan="2"><p>62</p></td><td><p>40.3</p><p>(28.1, 53.6)</p></td><td><p>8.9</p><p>(6.8, 11.8)</p></td></tr><tr><td rowspan="3"><p>Post-booster</p></td><td><p>month 1</p></td><td><p>58</p></td><td><p>100.0</p><p>(93.8, 100.0)</p></td><td><p>94.9</p><p>(74.6, 120.9)</p></td><td><p>57</p></td><td colspan="2"><p>100.0</p><p>(93.7, 100.0)</p></td><td colspan="3"><p>101.6</p><p>(83.1, 124.2)</p></td><td colspan="2"><p>62</p></td><td><p>96.8</p><p>(88.8, 99.6)</p></td><td><p>79.1</p><p>(60.6, 103.5)</p></td></tr><tr><td><p>month 12</p></td><td><p>58</p></td><td><p>65.5<br />(51.9, 77.5)</p></td><td><p>21.1<br />(14.2, 31.3)</p></td><td><p>54</p></td><td colspan="2"><p>74.1<br />(60.3, 85.0)</p></td><td colspan="3"><p>25.7<br />(17.7, 37.5)</p></td><td colspan="2"><p>62</p></td><td><p>77.4<br />(65.0, 87.1)</p></td><td><p>22.4<br />(16.4, 30.5)</p></td></tr><tr><td><p>month 26</p></td><td><p>0</p></td><td><p>NE<sup>(2)</sup></p></td><td><p>NE<sup>(2)</sup></p></td><td><p>33</p></td><td colspan="2"><p>78.8<br />(61.1, 91.0)</p></td><td colspan="3"><p>24.4<br />(16.1, 36.8)</p></td><td colspan="2"><p>42</p></td><td><p>59.5<br />(43.3, 74.4)</p></td><td><p>14.5<br />(9.9, 21.3)</p></td></tr><tr><td rowspan="6"><p><strong>B44</strong></p></td><td rowspan="3"><p>Post-primary</p></td><td><p>month 1</p></td><td><p>58</p></td><td><p>86.2</p><p>(74.6, 93.9)</p></td><td><p>46.3</p><p>(31.7, 67.8)</p></td><td><p>57</p></td><td colspan="2"><p>89.5</p><p>(78.5, 96.0)</p></td><td colspan="3"><p>50.2</p><p>(35.3, 71.3)</p></td><td colspan="2" style="vertical-align:top"><p>60</p></td><td><p>81.7</p><p>(69.6, 90.5)</p></td><td><p>35.5</p><p>(24.5, 51.4)</p></td></tr><tr><td><p>month 12</p></td><td><p>100</p></td><td><p>24.0</p><p>(16.0, 33.6)</p></td><td><p>6.4</p><p>(5.2, 7.8)</p></td><td><p>111</p></td><td colspan="2"><p>22.5</p><p>(15.1, 31.4)</p></td><td colspan="3"><p>6.0</p><p>(5.1, 7.2)</p></td><td colspan="2"><p>115</p></td><td><p>16.5</p><p>(10.3, 24.6)</p></td><td><p>5.6</p><p>(4.8, 6.5)</p></td></tr><tr><td><p>month 48</p></td><td><p>57</p></td><td><p>36.8</p><p>(24.4, 50.7)</p></td><td><p>8.3</p><p>(6.3, 11.0)</p></td><td><p>57</p></td><td colspan="2"><p>35.1</p><p>(22.9, 48.9)</p></td><td colspan="3"><p>7.6</p><p>(5.8, 10.0)</p></td><td colspan="2"><p>62</p></td><td><p>12.9</p><p>(5.7, 23.9)</p></td><td><p>4.6</p><p>(4.1, 5.1)</p></td></tr><tr><td rowspan="3"><p>Post-booster</p></td><td><p>month 1</p></td><td><p>59</p></td><td><p>100.0</p><p>(93.9, 100.0)</p></td><td><p>137.3</p><p>(100.3, 188.0)</p></td><td><p>58</p></td><td colspan="2"><p>100.0</p><p>(93.8, 100.0)</p></td><td colspan="3"><p>135.9</p><p>(108.0, 171.0)</p></td><td colspan="2"><p>61</p></td><td><p>93.4</p><p>(84.1, 98.2)</p></td><td><p>74.2</p><p>(51.6, 106.8)</p></td></tr><tr><td><p>month 12</p></td><td><p>56</p></td><td><p>75.0<br />(61.6, 85.6)</p></td><td><p>23.2<br />(16.2, 33.2)</p></td><td><p>53</p></td><td colspan="2"><p>81.1<br />(68.0, 90.6)</p></td><td colspan="3"><p>24.3<br />(17.8, 33.3)</p></td><td colspan="2"><p>61</p></td><td><p>59.0<br />(45.7, 71.4)</p></td><td><p>13.3<br />(9.7, 18.3)</p></td></tr><tr><td><p>month 26</p></td><td><p>0</p></td><td><p>NE<sup>(2)</sup></p></td><td><p>NE<sup>(2)</sup></p></td><td><p>33</p></td><td colspan="2"><p>66.7<br />(48.2, 82.0)</p></td><td colspan="3"><p>16.0<br />(10.4, 24.7)</p></td><td colspan="2"><p>43</p></td><td><p>62.8<br />(46.7, 77.0)</p></td><td><p>13.6<br />(9.8, 18.9)</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong>Composite<sup>(3)</sup></strong></p></td></tr><tr><td rowspan="6"><p>&nbsp;</p></td><td rowspan="3"><p>Post-primary</p></td><td><p>month 1</p></td><td><p>57</p></td><td><p>80.7</p><p>(68.1, 90.0)</p></td><td><p>NE</p></td><td><p>55</p></td><td colspan="2"><p>87.3</p><p>(75.5, 94.7)</p></td><td colspan="3"><p>NE</p></td><td colspan="2"><p>57</p></td><td><p>77.2</p><p>(64.2, 87.3)</p></td><td><p>NE</p></td></tr><tr><td><p>month 12</p></td><td><p>55</p></td><td><p>10.9</p><p>(4.1, 22.2)</p></td><td><p>NE</p></td><td><p>51</p></td><td colspan="2"><p>13.7</p><p>(5.7, 26.3)</p></td><td colspan="3"><p>NE</p></td><td colspan="2"><p>49</p></td><td><p>20.4</p><p>(10.2, 34.3)</p></td><td><p>NE</p></td></tr><tr><td><p>month 48</p></td><td><p>51</p></td><td><p>19.6</p><p>(9.8, 33.1)</p></td><td><p>NE</p></td><td><p>53</p></td><td colspan="2"><p>30.2</p><p>(18.3, 44.3)</p></td><td colspan="3"><p>NE</p></td><td colspan="2"><p>61</p></td><td><p>9.8</p><p>(3.7, 20.2)</p></td><td><p>NE</p></td></tr><tr><td rowspan="3"><p>Post-booster</p></td><td><p>month 1</p></td><td><p>56</p></td><td><p>100</p><p>(93.6, 100.0)</p></td><td><p>NE</p></td><td><p>55</p></td><td colspan="2"><p>100.0</p><p>(93.5, 100.0)</p></td><td colspan="3"><p>NE</p></td><td colspan="2"><p>59</p></td><td><p>91.5</p><p>(81.3, 97.2)</p></td><td><p>NE</p></td></tr><tr><td><p>month 12</p></td><td><p>53</p></td><td><p>52.8<br />(38.6, 66.7)</p></td><td><p>NE</p></td><td><p>48</p></td><td colspan="2"><p>64.6<br />(49.5, 77.8)</p></td><td colspan="3"><p>NE</p></td><td colspan="2"><p>57</p></td><td><p>61.4<br />(47.6, 74.0)</p></td><td><p>NE</p></td></tr><tr><td><p>month 26</p></td><td><p>0</p></td><td><p>NE<sup>(2)</sup></p></td><td><p>NE</p></td><td><p>27</p></td><td colspan="2"><p>48.1<br />(28.7, 68.1)</p></td><td colspan="3"><p>NE</p></td><td colspan="2"><p>36</p></td><td><p>44.4<br />(27.9, 61.9)</p></td><td><p>NE</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p>Abbreviations: hSBA=serum bactericidal assay using human complement; NE=not evaluated; GMT=geometric mean titre.</p><p><sup>(1)</sup> All strains used a 1:8 titre threshold except A22 which was 1:16.</p><p><sup>(2)</sup> Subjects were not followed beyond 12 months post booster.</p><p><sup>(3)</sup> Proportion of subjects with a composite of hSBA titres &ge; 1:8 or 16 for all four primary strains combined.</p><p>Serum samples were analysed concurrently in the same serology campaign for all time points except the 12 months post‑primary dose time point for which results are from the interim analysis.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Immunogenicity in individuals 1 to 9&nbsp;years of age</em></p><p><em>&nbsp;</em></p><p>The immunogenicity of Trumenba (0-, 2- and 6-month schedule) in toddlers and children 1 to 9 years of age was evaluated in 2 Phase 2 studies. At 1 month following series completion, 81.4% to 100% of subjects achieved a defined hSBA titre threshold against the 4 primary meningococcal test strains (defined as hSBA &ge;&nbsp;1:16 for A22; &ge;&nbsp;1:8 for A56, B24 and B44) compared to 0.4% to 6.5% at baseline.</p><p>&nbsp;</p><p>Persistence data following primary series completion in toddlers 1 to &lt;&nbsp;2 years of age indicate that 12.4%, 59.1%, 10.3%, and 40.4% at 6&nbsp;months and 3.7%, 22.8%, 3.7%, and 12.5% at 24 months after series completion maintained hSBA titres &ge;&nbsp;1:8 or 1:16 against the primary test strains A22, A56, B24 and B44, respectively. An anamnestic response was observed when these children received a booster dose at approximately 24 months after primary series completion at 3 to 5 years of age, with 92.6% to 100.0% achieving hSBA titres &ge;&nbsp;1:8 or 1:16 against the 4 primary strains.</p><p>&nbsp;</p><p>In children 2 to 9 years of age, 6&nbsp;months following series completion, 32.5%, 82.4%, 15.5% and 10.4% of participants maintained hSBA titres &ge;&nbsp;1:8 or 1:16 against the primary test strains A22, A56, B24 and B44, respectively. There are no persistence data beyond 6 months or booster dose data in this age group.</p><p>&nbsp;</p><p>See section 4.2 for information on use in children 1 to 9 years of age.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Trumenba in one or more subsets of the paediatric population for prevention of invasive meningococcal disease caused by <em>N. meningitidis</em> serogroup B (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity and reproduction and developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride</p><p>Histidine</p><p>Polysorbate 80 (E433)</p><p>Water for injections</p><p>For adsorbent, see section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not mix Trumenba with other vaccines or medicinal products in the same syringe.</p><p>&nbsp;</p><p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life : 4 years.

Do not use Trumenba after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C‑8&nbsp;&deg;C).</p><p>Syringes should be stored in the refrigerator horizontally to minimize the re-dispersion time.</p><p>Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5 ml suspension in a pre-filled syringe (Type I glass) with plastic Luer Lok adapter, chlorobutyl rubber plunger stopper, and a synthetic isoprene bromobutyl rubber tip cap with a plastic rigid tip cap cover with or without needle. The tip cap and rubber plunger of the pre-filled syringe are not made with natural rubber latex.</p><p>&nbsp;</p><p>Pack sizes of 1 pre-filled syringes, with needle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>During storage, a white deposit and clear supernatant may be observed in the pre-filled syringe containing the suspension.</p><p>&nbsp;</p><p>Before use, the pre-filled syringe should be shaken vigorously to ensure that a homogeneous white suspension is obtained.</p><p>&nbsp;</p><p>Do not use the vaccine if it cannot be re‑suspended.</p><p>&nbsp;</p><p>The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG, Belgium

MANUFACTURERED BY

Pfizer Ireland Pharmaceuticals
Grange Castle Business Park, Dublin, Ireland


PACKED & RELEASED BY

Pfizer Manufacturing Belgium NV
Puurs, Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>